Palivizumab (Synagis)

Indications

  • Respiratory Syncytial Virus (RSV) (see Respiratory Syncytial Virus, [[Respiratory Syncytial Virus]])
    • No clinical benefit in established RSV infection
    • Licensed for the prevention of serious RSV lower respiratory tract disease in children at high risk of RSV infection (prematurity, bronchopulmonary dysplasia, congenital heart disease)

Pharmacology

  • Respiratory Syncytial Virus-Specific Humanized Monoclonal Antibody

Administration

  • xxxx

Dose Adjustment

  • Hepatic:
  • Renal:

Adverse Effects

Other Adverse Effects

  • xxx
  • xxx
  • xxx

References

  • xxxx